Contact

Our portfolio

PacingCure

PacingCure is pioneering gene therapy solutions to cure heart conditions that results in pacing issues. The company focuses on developing biological pacemakers for patients who cannot use conventional electronic pacemaker devices. Their research explores various transgenes and delivery systems to modulate heart pacing. PacingCure is dedicated to advancing cardiac care through innovative gene therapy.

  • Institute: Amsterdam UMC
Industry: Cardiology, Gene Therapy, Therapeutics
  • Founding year: 2016
Visit website

Want to get in contact about PacingCure?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

SigmaScreening
Developing a painless and more accurate mammography technology for breast cancer detection.
Scyfer
Developing advanced machine learning and deep learning technologies, Scyfer specializes in applying these solutions across various industries, including industry, media, and healthcare.
AviSia Therapeutics
Modulating immune responses with glycan-modified antigens for the treatment of Type 1 Diabetes.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
SigmaScreening
Developing a painless and more accurate mammography technology for breast cancer detection.
Scyfer
Developing advanced machine learning and deep learning technologies, Scyfer specializes in applying these solutions across various industries, including industry, media, and healthcare.
AviSia Therapeutics
Modulating immune responses with glycan-modified antigens for the treatment of Type 1 Diabetes.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
Explore full AAV portfolio
Contact